Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Friedreich Ataxia - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Friedreich Ataxia - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides top ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...

Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide ...

Lions postgame injury report after season-ending loss to Commanders, with updates on Amik Robertson, Penei Sewell and more ...

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), ...

The data analysis is being finalized, and we remain on track to report topline results in early February ... Parkinson’s disease, and Friedreich’s Ataxia. New, non-clinical data was presented that ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...